Recently, the development of poly (ADP-Ribose) polymerase (PARP) inhibitors for treatment in BRCA-mutated cancers has highlighted the potential targeting of DNA repair proteins as a therapeutic approach. This evidence concerns the gene XRCC6P5 and cancer.